Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of SAL0140 in Healthy Chinese Subjects
NCT07051603Phase 1Recruiting
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SAL0140 in hypertension (HTN) (3 arms), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. Primary endpoints: The rate of Adverse events and The rate of normality or abnormality of electrocardiogram. Started Jun 2025; status: recruiting.
02
Drugs
SAL0140
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07051603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07051603.